Homeomorphic Matlab Model of Myopia Development
- *Corresponding Author:
- Dr. Hung GK
Dept. of Biomedical Engineering
Rutgers University, 599 Taylor Road,
Piscataway, NJ 08854,
Tel: 732-445-4500, Ext. 6306,
E-mail: [email protected]
Received Date:February 17, 2010; Accepted Date: April 07, 2010; Published Date: April 07, 2010
Citation: Hung GK, Fiedler AJ, Ciuffreda KJ (2010) Homeomorphic Matlab Model of Myopia Development. J Comput Sci Syst Biol 3:030-039. doi: 10.4172/jcsb.1000052
Copyright: © 2010 Hung GK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A homeomorphic biomechanical model of the eye based on the Incremental Retinal-Defocus Theory (IRDT) was developed to simulate myopic and hyperopic growth under different optical defocus conditions. The IRDT states that the time-integrated reduction in retinal-image defocus magnitude decreases the rate of retinal neuromodulator release, which in turn decreases the rate of proteoglycan synthesis and reduces scleral structural integrity, thus resulting in axial elongation and myopia development. A homeomorphic biomechanical model of the eye was constructed to test the IRDT based only on optical defocus and its resultant contribution to mechanical forces acting on the components of the eye. The Matlab simulation results showed a more fl attened oblate shape for myopic defocus, and a more elongated prolate shape with hyperopic defocus. Thus, the homeomorphic biomechanical model of the eye was able to simulate the emmetropization mechanism using only the forces acting on the masses at the nodes. In addition, neurochemicals injected at local retinal regions modifi ed the spring constants to result in predicted changes in ocular deformation. The fi ndings have clinical implications with respect to basic theories of myopia development, as well as future therapeutic use of direct ocular drug delivery to control human myopia.